Company Overview - Theriva™ Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases in areas of high unmet need [3] - The company is advancing a new oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery to enhance tumor cell death and improve access to co-administered cancer therapies [3] Lead Candidates - The lead candidates include: - VCN-01, an oncolytic adenovirus that selectively replicates within tumor cells and degrades the tumor stroma barrier [3] - SYN-004 (ribaxamase), designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract to prevent microbiome damage and reduce acute graft-versus-host disease in transplant recipients [3] - SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase intended to treat local GI and systemic diseases [3] Upcoming Conference Participation - Theriva's management will present at the Cancer Advocacy Group of Louisiana NeauxCancer 2025 Conference from March 27th-29th, 2025 [1] - A company presentation is scheduled for the Innovation track on March 28th at 9:00 am, highlighting emerging biotech and healthcare companies in oncology [2] - Management will be available for one-on-one meetings with interested investors during the conference [2]
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference